Ví dụ về việc sử dụng Protease inhibitor trong Tiếng anh và bản dịch của chúng sang Tiếng việt
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
Camostat(INN; development code FOY-305) is a serine protease inhibitor.
Protein Z-related protease inhibitor(ZPI) Degrades factors X(in presence of protein Z) and XI(independently).
The most common HAART treatment consists of two NRTIs andone NNRTI or a protease inhibitor.
Amprenavir(Agenerase, GlaxoSmithKline) is a protease inhibitor used to treat HIV infection.
Except for A364V, mutations in the CA/SP1 cleavage site have showed toresult in fitness deficits when combined with protease inhibitor resistance.
All these medicines contain a hepatitis C virus(HCV) protease inhibitor and are not indicated for use in patients with moderate to sever….
A study published in the Nutrition and Cancer journal discovered that these legumes can prevent breastcancer thanks to their anti-cancer agents called protease inhibitor concentrates.
Glecaprevir(INN,[1]) is a hepatitis C virus(HCV) nonstructural(NS) protein 3/4A protease inhibitor that was identified jointly by AbbVie and Enanta Pharmaceuticals.
It has been shown that protease inhibitor resistance can result in an increase in the occurrence of mutations within the downstream QVT motif.[ 10][ 11][ 12][ 13].
Amprenavir(original brand name Agenerase, GlaxoSmithKline) is a protease inhibitor used to treat HIV infection.
Boceprevir(INN, trade name Victrelis) is a protease inhibitor used to treat hepatitis caused by hepatitis C virus(HCV) genotype 1.[2][3] It binds to the HCV nonstructural protein 3 active site.
It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir(lopinavir/ritonavir).[1].
Antithrombin(AT), a serine protease inhibitor, is the major plasma inhibitor of coagulation proteases.[16] LMWHs inhibit the coagulation process through binding to AT via a pentasaccharide sequence.
Vaniprevir(MK-7009) is a macrocyclic hepatitis C virus(HCV) NS3/4A protease inhibitor, developed by Merck& Co., which is currently in clinical testing.[1].
A 1996 study of protease inhibitor polymorphism concludes that"a genetic correlation could be present between Sarcidano Horses and ancient Spanish horses as reported by historical documents about horse breeding in Sardinia".
Voxilaprevir is a hepatitis C virus(HCV) nonstructural(NS)protein 3/4A protease inhibitor(by Gilead) that is used in combination with sofosbuvir and velpatasvir.
This principle was first exploited in the drug Kaletra(Abbott),which is a combination of ritonavir with the protease inhibitor lopinavir at a ratio(v/v) of 1:4.
Indinavir(IDV; trade name Crixivan, manufactured by Merck) is a protease inhibitor used as a component of highly active antiretroviral therapy(HAART) to treat HIV infection and AID.
Using combinations of NRTIs was in practice prior to the second FDA approval andthe triple drug combinations with dual NRTIs and a protease inhibitor(PI) were not far off by this time.
Indinavir(IDV; trade name Crixivan, manufactured by Merck) is a protease inhibitor used as a component of highly active antiretroviral therapy to treat HIV/AIDS.
Daclatasvir should be combined with other medications, which may include other direct-acting antivirals that work differently- sofosbuvir(Sovaldi)or the HCV protease inhibitor asunaprevir(Sunvepra)- or pegylated interferon and ribavirin.
It was the first-in-class NS3/4A protease inhibitor to enter clinical development and tested in human.[2] Ciluprevir is a potent competitive reversible inhibitor of NS3/4A protease from HCV genotype 1a(Ki= 0.3 nM) and 1b(Ki= 0.66 nM).
Lasinavir(INN,[1] previously known as BMS-234475 and CGP-61755)is an experimental peptidomimetic protease inhibitor researched by Novartis and Bristol-Myers Squibb as a treatment for HIV infection.
Obviously, the combination of peginterferon, ribavirin and a first generation protease inhibitor(boceprevir or telaprevir) is not an option for patients with absolute contraindications to interferon and it is also a poor choice for individuals with comorbidities or those who are old.
Elbasvir is a drug approved by the FDA in January 2016[1] for the treatment of hepatitis C. It was developed by Merck and completed Phase III trials,used in combination with the NS3/4A protease inhibitor grazoprevir under the trade name Zepatier, either with or without ribavirin.[2].
Additionally, in existence are a fixed-dose combination of cobicistat and protease inhibitor darunavir(darunavir/cobicistat; marketed as Prezcobix by Janssen Therapeutics), and a fixed-dose combination of cobicistat and protease inhibitor atazanavir(atazanavir/cobicistat; marketed as Evotaz by Bristol-Myers Squibb).
Sleasman's analysis is based on data collected during the first U.S. clinical trial of children treated for aids with a so-called drug cocktail--a combinationof medications that includes a protease inhibitor, the class of drugs shown to interfere effectively in replication of the HIV virus.
There is some confirmation that this is part of theway intervened by a protein in potatoes called protease inhibitor 2, which is accepted to have useful impacts on appetite hormones, however this has to be studied further.
It is a fixed dose combination drug containing 300 mg of atazanavir and 150 mg of cobicistat.[1]Atazanavir is an HIV protease inhibitor and cobicistat blocks the body's metabolism of atazanavir by the enzyme CYP3A prolonging its effectiveness.
It is a fixed dose combination drug containing 800 mg of darunavir and 150 mg of cobicistat.[1]Darunavir is an HIV protease inhibitor and cobicistat increases the effectiveness of darunavir by blocking its metabolism by the enzyme CYP3A.